Skip to content

Medicxi Ventures Management (Jersey) Ltd

Follow

13F filer, CIK 1715579, ST. HELIER, Jersey

Medicxi Ventures Management (Jersey) Ltd reported $177,424,615 across 3 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-04.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-332000

Period
2026-06-30
Reported value
$177M
Holdings
3
Top 10 weight
100%
New
0
Sold out
1

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CNTAexited-19,963,157-$793M
NAMSreduced-465,543-$15.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001193125-26-332000, largest first. % of portfolio is the value over $177,424,615, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 7,464,572 shares; 2024Q4: 7,464,572 shares; 2025Q1: 7,464,572 shares; 2025Q2: 7,464,572 shares; 2025Q3: 7,464,572 shares; 2025Q4: 7,464,572 shares; 2026Q1: 7,464,572 shares; 2026Q2: 7,464,572 shares 7,464,572$81M45.65%0Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,869,565 shares; 2024Q4: 2,869,565 shares; 2025Q1: 2,869,565 shares; 2025Q2: 2,869,565 shares; 2025Q3: 2,869,565 shares; 2025Q4: 2,869,565 shares; 2026Q1: 2,674,182 shares; 2026Q2: 2,208,639 shares 2,208,639$74.9M42.19%-465,543Timeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,039,892 shares; 2024Q4: 3,039,892 shares; 2025Q1: 3,039,892 shares; 2025Q2: 3,039,892 shares; 2025Q3: 3,039,892 shares; 2025Q4: 3,039,892 shares; 2026Q1: 3,039,892 shares; 2026Q2: 3,039,892 shares 3,039,892$21.6M12.16%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CNTACENTESSA PHARMACEUTICALS PLC19,963,157$793Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-332000 base2026-08-04acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001193125-26-332000 Quarter ended 2026-06-302026-08-04acceptance time not in the bulk data set
13F-HR 0001193125-26-166701 Quarter ended 2026-03-312026-04-21acceptance time not in the bulk data set
13F-HR 0001193125-26-020931 Quarter ended 2025-12-312026-01-23acceptance time not in the bulk data set
13F-HR 0001193125-25-242131 Quarter ended 2025-09-302025-10-17acceptance time not in the bulk data set
13F-HR 0000950123-25-006205 Quarter ended 2025-06-302025-07-08acceptance time not in the bulk data set
13F-HR 0000950123-25-003449 Quarter ended 2025-03-312025-04-11acceptance time not in the bulk data set
13F-HR 0000950123-25-000517 Quarter ended 2024-12-312025-01-23acceptance time not in the bulk data set
13F-HR 0000950123-24-009687 Quarter ended 2024-09-302024-10-15acceptance time not in the bulk data set
13F-HR 0000950123-24-006607 Quarter ended 2024-06-302024-07-16acceptance time not in the bulk data set
13F-HR 0000950123-24-003318 Quarter ended 2024-03-312024-04-15acceptance time not in the bulk data set
13F-HR 0000950123-24-000564 Quarter ended 2023-12-312024-02-01acceptance time not in the bulk data set
13F-HR 0000950123-23-008852 Quarter ended 2023-09-302023-10-18acceptance time not in the bulk data set
13F-HR 0000950123-23-006158 Quarter ended 2023-06-302023-07-19acceptance time not in the bulk data set
13F-HR 0000950123-23-003438 Quarter ended 2023-03-312023-04-27acceptance time not in the bulk data set
13F-HR 0000950123-23-000545 Quarter ended 2022-12-312023-01-31acceptance time not in the bulk data set
13F-HR 0000950123-22-010439 Quarter ended 2022-09-302022-10-25acceptance time not in the bulk data set
13F-HR/A 0000950123-22-007699 Quarter ended 2022-06-302022-08-03acceptance time not in the bulk data set
13F-HR 0000950123-22-007682 Quarter ended 2022-06-302022-08-03acceptance time not in the bulk data set
13F-HR 0000950123-22-005321 Quarter ended 2022-03-312022-05-12acceptance time not in the bulk data set
13F-HR 0000950123-22-000871 Quarter ended 2021-12-312022-02-03acceptance time not in the bulk data set
13F-HR 0000950123-21-014511 Quarter ended 2021-09-302021-11-10acceptance time not in the bulk data set
13F-HR 0000950123-21-009518 Quarter ended 2021-06-302021-08-03acceptance time not in the bulk data set
13F-HR 0000950123-21-005800 Quarter ended 2021-03-312021-05-11acceptance time not in the bulk data set
13F-HR 0000950123-21-001794 Quarter ended 2020-12-312021-02-12acceptance time not in the bulk data set
13F-HR 0000950123-20-010496 Quarter ended 2020-09-302020-10-27acceptance time not in the bulk data set
13F-HR 0000950123-20-007820 Quarter ended 2020-06-302020-08-07acceptance time not in the bulk data set
13F-HR 0000950123-20-004479 Quarter ended 2020-03-312020-05-12acceptance time not in the bulk data set
13F-HR 0000950123-20-001358 Quarter ended 2019-12-312020-02-11acceptance time not in the bulk data set